$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Altria (MO) delivered a strong Q2 FY2025 EPS beat on significant margin expansion and robust oral tobacco growth, raising full-year guidance despite modest revenue declines and ongoing regulatory risks.

# Altria Group Delivers Strong Q2 FY2025 EPS Beat on Margin Expansion Despite Modest Revenue Decline

---

## Executive Summary

- **Altria Group (MO) reported Q2 FY2025 adjusted diluted EPS of $1.44, up 8.3% YoY and above consensus,** driven by robust margin expansion and strong volume growth in the oral tobacco segment, despite a slight revenue decline.
- **Operating income margin surged to 52.9% (+11.6pp YoY),** reflecting effective cost control and operational efficiency across both smokeable and oral product lines.
- **Management struck a cautiously bullish tone,** raising full-year adjusted EPS guidance to $5.35–$5.45 (3–5% YoY growth), citing confidence in continued margin improvement and capital returns.
- **Regulatory risks remain,** particularly with the FDA’s recent JUUL authorization adding complexity to the e-vapor landscape, but Altria’s diversified portfolio and cost discipline provide resilience.
- **Short-term catalyst watch:** Positive analyst upgrades, reduced short interest, and ongoing share repurchases are likely to support near-term stock performance.

---

## Performance Snapshot

| Metric                | Reported   | Consensus | Surprise | YoY Change |
|-----------------------|------------|-----------|----------|------------|
| Revenue (Net)         | $6.102B    | $6.10B    | +$0.002B | -1.7%      |
| Revenue (ex-Excise)   | $5.290B    | $5.28B    | +$0.01B  | +0.2%      |
| Adjusted Diluted EPS  | $1.44      | $1.39     | +$0.05   | +8.3%      |
| Reported Diluted EPS  | $1.41      | $1.39     | +$0.02   | -36.2%*    |
| Operating Margin      | 52.9%      | —         | —        | +11.6pp    |
| Oral Tobacco Volumes  | —          | —         | —        | +26.5%     |

*YoY decline due to prior-year one-off gain on IQOS rights sale.

---

## Earnings Quality

Altria Group’s Q2 earnings quality was underpinned by **significant margin expansion** rather than top-line growth. The company’s **operating income margin rose to 52.9%**, with both the oral tobacco (68.7% OCI margin, +3.1pp YoY) and smokeable segments (64.5% OCI margin, +2.9pp YoY) contributing. This margin strength reflects **disciplined cost management and operational efficiency**, offsetting modest revenue declines. The divergence between flat-to-down sales and robust EPS growth highlights the effectiveness of Altria’s cost containment and product mix optimization.

---

## Management Commentary & Guidance

Management’s tone was **cautiously bullish**. CEO Billy Gifford emphasized the company’s **core segment strength, ongoing cost discipline, and commitment to shareholder returns**. The **raised FY2025 adjusted EPS guidance to $5.35–$5.45** (3–5% YoY growth) signals confidence in sustaining margin gains and capital allocation, particularly in the second half. Assumptions include continued volume growth in oral tobacco, stable pricing, and further operational efficiencies.

---

## Key Risks

- **Regulatory:** The FDA’s recent JUUL authorization, while not directly impacting Altria, increases competitive and regulatory uncertainty in the e-vapor category.
- **Revenue Pressure:** Modest revenue declines could persist if cigarette volumes continue to contract faster than oral tobacco growth.
- **Cost Inflation:** Potential macroeconomic or FX headwinds could pressure input costs, though current trends are favorable.

---

## Expected Market Reaction

Analyst sentiment has turned more positive, with recent **upgrades from UBS and Stifel** and a reduction in short interest. The **combination of an EPS beat, margin expansion, and raised guidance** is expected to drive a **constructive market reaction**, with investors likely to reward Altria’s margin resilience and capital return strategy.

---

## Final Takeaway

**Q2 FY2025 was a strong quarter for Altria Group,** with the market potentially underestimating the sustainability of its margin-driven EPS growth amid modest revenue trends. The company’s cost discipline, robust oral tobacco growth, and enhanced capital returns position it well, though regulatory risks warrant monitoring. 

**Upcoming catalysts:**  
- Q3 2025 earnings and further updates on margin trends  
- Regulatory developments in the e-vapor category

Altria’s ability to deliver on its raised guidance and maintain margin strength will be key to sustaining positive investor sentiment.

Altria (MO): Margin Expansion Drives EPS Beat and Guidance Raise

Altria’s Q2 outlook is supported by strong margin expansion and cost savings, offsetting cigarette volume declines and positioning the company for a potential earnings surprise.

# Altria Group (MO): Margin Resilience and Category Shifts Set the Stage for Q2 Earnings Surprise

## Executive Summary

We maintain a **Neutral-to-Bullish** outlook for Altria Group (MO) heading into Q2 FY2025, as the company’s robust pricing power and operational efficiency initiatives are expected to offset persistent volume declines in its core cigarette business. **Q1 FY2025 revenue of $5.26 billion** and a **gross margin of 61.8%** highlight management’s ability to defend profitability despite a **13.7% YoY drop in cigarette shipments**. The market may be underestimating the near-term margin upside from the “Optimize & Accelerate” cost program, which is targeting **$100–$125 million in pre-tax savings**. However, regulatory risks in the e-vapor segment and continued volume headwinds remain key watchpoints for the upcoming quarter.

## Recent Trends Signal What’s Next

Altria’s last two quarters reveal a clear pattern: while traditional volume metrics remain under pressure, margin expansion and category mix improvements are driving earnings stability.

- **Q1 FY2025 revenue**: $5.26B (down slightly YoY, but stable sequentially)
- **Gross margin**: 61.8% (up 120 bps YoY)
- **Adjusted operating margin**: up 2.7 percentage points YoY in smokeable products
- **EPS**: $1.15 (flat YoY, up 2% QoQ)

### Revenue, Margin, and EPS Trend Table

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | EPS ($) |
|--------------|--------------|------------------|----------------------|---------|
| Q2 FY2024    | 5.44         | 60.2             | 54.1                 | 1.10    |
| Q3 FY2024    | 5.41         | 60.7             | 55.0                 | 1.13    |
| Q4 FY2024    | 5.32         | 61.0             | 56.2                 | 1.14    |
| Q1 FY2025    | 5.26         | 61.8             | 56.8                 | 1.15    |

**Key takeaway:** Despite top-line softness, margin expansion is supporting EPS, a trend likely to persist in Q2.

## Management’s Forward Tone and Positioning

Management’s Q1 call and recent filings reflect a **measured optimism**. The tone has shifted from “navigating headwinds” in prior quarters to “unlocking momentum” and “opportunity” in core brands and new categories.

- **Quote:** “We’re seeing early signs of normalization in demand for premium brands and remain confident in our pricing flexibility.” (Q1 2025 Earnings Call)
- **Quote:** “Our ‘Optimize & Accelerate’ program is on track to deliver meaningful cost savings in 2025.” (Q1 2025 Earnings Call)

Compared to Q4 FY2024, when management emphasized “uncertainty” and “regulatory overhang,” the current language signals greater confidence in margin recovery and cost control as levers for near-term performance.

## KPI Trends & Upcoming Quarter Drivers

Three KPIs will be pivotal for Q2 results:

- **Cigarette shipment volumes:** Down 13.7% YoY in Q1; likely to remain under pressure, but rate of decline may moderate.
- **on! brand volume:** Up 18.0% YoY; continued double-digit growth expected, supporting mix and margin.
- **Adjusted operating margin:** Improved 2.7 percentage points YoY in Q1; further gains possible from cost initiatives.

### KPI Movement Table

| KPI                    | Q1 FY2024 | Q4 FY2024 | Q1 FY2025 | YoY Change | QoQ Change | Q2 FY2025E |
|------------------------|-----------|-----------|-----------|------------|------------|------------|
| Cigarette Shipments    | -10.5%    | -12.2%    | -13.7%    | -3.2 pts   | -1.5 pts   | -12% to -14% |
| on! Brand Volume       | +15.0%    | +16.5%    | +18.0%    | +3.0 pts   | +1.5 pts   | +16% to +19% |
| Adj. Operating Margin  | 54.1%     | 56.2%     | 56.8%     | +2.7 pts   | +0.6 pts   | 56.5%–57.5% |

**Implication:** If on! growth and margin expansion persist, Q2 EPS could surprise to the upside even if cigarette volumes remain weak.

## Missed by the Street

A key overlooked signal is the **potential for cost recovery and margin expansion** from the “Optimize & Accelerate” program. While the $873M NJOY impairment drew headlines, management’s guidance for **$100–$125M in pre-tax cost savings** is not fully reflected in consensus models. Additionally, the stabilization in oral tobacco share (+1.8 pts for on!) suggests a more resilient category mix than the Street expects.

- **Quote:** “We expect to realize the majority of targeted cost savings in the second half of 2025.” (Q1 2025 Earnings Call)

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Revenue ($B) | EPS ($) | Operating Margin (%) | Key Assumptions |
|----------|--------------|---------|----------------------|-----------------|
| Bull     | 5.32–5.38    | 1.18–1.20 | 57.0–57.5           | Accelerated cost savings, on! outperformance, regulatory relief |
| Base     | 5.24–5.30    | 1.14–1.16 | 56.5–57.0           | Stable pricing, moderate volume decline, cost discipline |
| Bear     | 5.18–5.23    | 1.10–1.13 | 55.5–56.0           | Steeper volume drop, regulatory setbacks, cost inflation |

**Most likely scenario:** **Base case**—cost savings and pricing offset volume declines, with EPS stable to slightly up QoQ.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter      | Revenue ($B) | EPS ($) | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|---------|------------------|----------------------|
| Q2 FY2024    | 5.44         | 1.10    | 60.2             | 54.1                 |
| Q3 FY2024    | 5.41         | 1.13    | 60.7             | 55.0                 |
| Q4 FY2024    | 5.32         | 1.14    | 61.0             | 56.2                 |
| Q1 FY2025    | 5.26         | 1.15    | 61.8             | 56.8                 |

### KPI Movement Table

| KPI                    | Q1 FY2024 | Q4 FY2024 | Q1 FY2025 | YoY Change | QoQ Change |
|------------------------|-----------|-----------|-----------|------------|------------|
| Cigarette Shipments    | -10.5%    | -12.2%    | -13.7%    | -3.2 pts   | -1.5 pts   |
| on! Brand Volume       | +15.0%    | +16.5%    | +18.0%    | +3.0 pts   | +1.5 pts   |
| Adj. Operating Margin  | 54.1%     | 56.2%     | 56.8%     | +2.7 pts   | +0.6 pts   |

### Key Management Quotes

1. **“We’re seeing early signs of normalization in demand for premium brands and remain confident in our pricing flexibility.”**  
   *Q1 2025 Earnings Call*  
   *Signals management’s confidence in offsetting volume declines with pricing.*

2. **“Our ‘Optimize & Accelerate’ program is on track to deliver meaningful cost savings in 2025.”**  
   *Q1 2025 Earnings Call*  
   *Highlights margin upside potential from cost initiatives.*

3. **“We expect to realize the majority of targeted cost savings in the second half of 2025.”**  
   *Q1 2025 Earnings Call*  
   *Suggests incremental margin improvement in H2, with some early benefit in Q2.*

4. **“We continue to face regulatory uncertainty in the e-vapor category, particularly with NJOY.”**  
   *Q1 2025 Earnings Call*  
   *Underscores ongoing risk to non-combustible segment revenue.*

5. **“on! delivered 18% volume growth and gained 1.8 share points in the oral tobacco category.”**  
   *Q1 2025 Earnings Call*  
   *Points to a key growth driver for Q2.*

6. **“We recognized an $873 million impairment on the NJOY segment, but remain committed to the category.”**  
   *Q1 2025 10-Q*  
   *Impairment is a one-off; focus remains on long-term category growth.*

7. **“We are maintaining our full-year adjusted EPS guidance of $5.30–$5.45, reflecting 2–5% growth.”**  
   *Q1 2025 Earnings Call*  
   *Signals management’s confidence in delivering on 2025 targets.*

---

**Bottom Line:**  
Altria’s Q2 will hinge on the interplay between cost discipline, pricing power, and category mix. While volume headwinds persist, margin levers and oral tobacco growth could drive a modest earnings beat if regulatory risks remain contained.

Altria (MO): Margin Strength Drives Q2 Upside Potential